Similarly, targeting CXCL12 induced rapid T-cell accumulation among PDAC cancer cells and acted synergistically with anti-PDL1 immunotherapy to reduce tumour burden in murine PDAC [76]. The gene discussed is CXCL12; the disease is cancer.